Clinical Trial Update: A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression [Phase 3]

View source ↗

Summary

A 52-week Phase 3 safety study of Saredutant in adult and elderly patients with depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Saredutant (saredutant)

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 3 | Status: COMPLETED